Boston Scientific's Rotablator Anticipated To Generate $15 mil. In Q4 Sales
This article was originally published in The Gray Sheet
Executive Summary
A limited reintroduction of Boston Scientific's original Rotablator rotational atherectomy device later this month is anticipated to generate $15 mil. in sales for the firm in the fourth quarter.
You may also be interested in...
Spectranetics Catheter Sales Benefiting From RotaLink Recall
Spectranetics placed 16 atherectomy lasers and saw sales of disposable coronary angioplasty catheters more than double in the third quarter, largely at the expense of Boston Scientific's RotaLink Plus atherectomy system, the company reported Nov. 30 at the BancBoston Robertson Stephens annual health care conference in New York City.
Spectranetics Catheter Sales Benefiting From RotaLink Recall
Spectranetics placed 16 atherectomy lasers and saw sales of disposable coronary angioplasty catheters more than double in the third quarter, largely at the expense of Boston Scientific's RotaLink Plus atherectomy system, the company reported Nov. 30 at the BancBoston Robertson Stephens annual health care conference in New York City.
PE Biosystems DNA Analyzer Demand, Strong Sales Boost Stock 26% In Q3
Continued strong demand for the ABI Prism 3700 DNA analyzer, order growth across a broad range of additional products and release of financial results ahead of some analysts' estimates contributed to a 25.9% jump in PE Biosystems' stock price during the third quarter.